Prognostic significance of fascin-1 and E-cadherin expression in laryngeal squamous cell carcinoma

European Journal of Cancer Prevention

Volumn 19, Issue 1, 2010, Pages 11-17

  Zou, Jian ^a   Yang, Hui ^a   Chen, Fei ^a   Zhao, Houyu ^a   Lin, Pin ^a   Zhang, Jie ^a   Ye, Huiping ^a   Wang, Lihong ^a   Liu, Shixi ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

E cadherin; Fascin 1; Immunohistochemistry; Laryngeal squamous cell carcinoma; Recurrence

Indexed keywords

FASCIN; UVOMORULIN;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; DISEASE FREE SURVIVAL; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LARYNX CARCINOMA; MAJOR CLINICAL STUDY; MALE; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; CADHERINS; CARCINOMA, SQUAMOUS CELL; CARRIER PROTEINS; FEMALE; FOLLOW-UP STUDIES; HUMANS; LARYNGEAL NEOPLASMS; MALE; MICROFILAMENT PROTEINS; MIDDLE AGED; PROGNOSIS; RECURRENCE; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 75149170539     PISSN: 09598278     EISSN: None     Source Type: Journal    
DOI: 10.1097/CEJ.0b013e32832f9aa6     Document Type: Article

References (33)

1. Adams JC (2004). Roles of fascin in cell adhesion and motility. Curr Opin Cell Biol 16:590-596.
2. Awada A, Lalami Y (2005). Molecular markers, molecular-targeted therapies and taxanes: how to integrate the progress into clinical research and practice for the management of head and neck cancers. Curr Opin Oncol 17:209-211.
3. Birner P, Schindl M, Obermair A, Plank C, Breitenecker G, Oberhuber G (2000). Overexpression of hypoxia-inducible factor 1alpha is a marker for an unfavorable prognosis in early-stage invasive cervical cancer. Cancer Res 6 0:4693-4696.
4. Bremnes RM, Veve R, Gabrielson E, Hirsch FR, Baron A, Bemis L, et al. (2002). High-throughput tissue microarray analysis used to evaluate biology and prognostic significance of the E-cadherin pathway in non-small-cell lung cancer. J Clin Oncol 20:2417-2428.
5. D'Cruz AK, Mulherkar R (2005). Optimizing treatment in head and neck cancers - are molecular markers the answer? Indian J Med Res 122:196-198.
6. Dabbs DJ, Kaplai M, Chivukula M, Kanbour A, Kanbour-Shakir A, Carter GJ (2007). The spectrum of morphomolecular abnormalities of the E-cadherin/ catenin complex in pleomorphic lobular carcinoma of the breast. Appl Immunohistochem Mol Morphol 15:260-266.
7. Diniz-Freitas M, Garcia-Caballero T, Antunez-Lopez J, Gandara-Rey JM, Garcia-Garcia A (2006). Reduced E-cadherin expression is an indicator of unfavourable prognosis in oral squamous cell carcinoma. Oral Oncol 4 2:190-200.
8. Goncharuk VN, Ross JS, Carlson JA (2002). Actin-binding protein fascin expression in skin neoplasia. J Cutan Pathol 29:430-438.
9. Gould Rothberg BE, Bracken MB (2006). E-cadherin immunohistochemical expression as a prognostic factor in infiltrating ductal carcinoma of the breast: a systematic review and meta-analysis. Breast Cancer Res Treat 1 00:139-148.
10. Hardavella G, Arkoumani E, Dalavanga Y, Galanis P, Agnantis NJ, Constantopoulos S, Stefanou D (2008). Prognostic impact of lymphangiogenesis and lymphatic invasion (CD105 expression) in small cell lung carcinoma. Anticancer Res 2 8:343-347.
11. Hashimoto Y, Shimada Y, Kawamura J, Yamasaki S, Imamura M (2004). The prognostic relevance of fascin expression in human gastric carcinoma. Oncology 67:262-270. (Pubitemid 39551711)
12. Hashimoto Y, Skacel M, Adams JC (2005a). Roles of fascin in human carcinoma motility and signaling: prospects for a novel biomarker? Int J Biochem Cell Biol 37:1787-1804.
13. Hashimoto Y, Ito T, Inoue H, Okumura T, Tanaka E, Tsunoda S, et al. (2005b). Prognostic significance of fascin overexpression in human esophageal squamous cell carcinoma. Clin Cancer Res 11:2597-2605. (Pubitemid 40569459)
14. Ji W, Guan C, Pan Z (2008). Analysis of curative effects on laryngeal carcinoma patients in the northeast region of China. Acta Otolaryngol 128:574-577.
15. Kashibuchi K, Tomita K, Schalken JA, Kume H, Yamaguchi T, Muto S, et al. (2006). The prognostic value of E-cadherin, alpha-, beta-, and gamma-catenin in urothelial cancer of the upper urinary tract. Eur Urol 49:839-845. Discussion 845.
16. Kawano T, Nakamura Y, Yanoma S, Kubota A, Furukawa M, Miyagi Y, Tsukuda M (2004). Expression of E-cadherin, and CD44s and CD44v6 and its association with prognosis in head and neck cancer. Auris Nasus Larynx 3 1:35-41.
17. Kureishy N, Sapountzi V, Prag S, Anilkumar N, Adams JC (2002). Fascins, and their roles in cell structure and function. Bioessays 24:350-361.
18. Lee TK, Poon RT, Man K, Guan XY, Ma S, Liu XB, et al. (2007a). Fascin over-expression is associated with aggressiveness of oral squamous cell carcinoma. Cancer Lett 254:308-315.
19. Lee YC, Pan HW, Peng SY, Lai PL, Kuo WS, Ou YH, Hsu HC (2007b). Overexpression of tumour-associated trypsin inhibitor (TATI) enhances tumour growth and is associated with portal vein invasion, early recurrence and a stage-independent prognostic factor of hepatocellular carcinoma. Eur J Cancer 43:736-744.
20. Leon X, Lopez M, Garcia J, Viza I, Gich I, Quer M (2008). Recurrent laryngeal squamous cell carcinoma: rTNM versus composite laryngeal recurrence staging system. Proposal for a modification of the CLRSS to improve patient classification. Head Neck 30:939-945.
21. Liu WW, Zeng ZY,Wu QL, Hou JH, Chen YY (2005). Overexpression of MMP-2 in laryngeal squamous cell carcinoma: a potential indicator for poor prognosis. Otolaryngol Head Neck Surg 132:395-400.
22. Luke CG, Yeoh E, Roder DM (2008). Exploring trends in laryngeal cancer incidence, mortality and survival: implications for research and cancer control. Asian Pac J Cancer Prev 9:397-402.
23. Mareel M, Leroy A (2003). Clinical, cellular, and molecular aspects of cancer invasion. Physiol Rev 83:337-376.
24. Marioni G, Marchese-Ragona R, Cartei G, Marchese F, Staffieri A (2006). Current opinion in diagnosis and treatment of laryngeal carcinoma. Cancer Treat Rev 3 2:504-515.
25. Mikami T, Saegusa M, Mitomi H, Yanagisawa N, Ichinoe M, Okayasu I (2001). Significant correlations of E-cadherin, catenin, and CD44 variant form expression with carcinoma cell differentiation and prognosis of extrahepatic bile duct carcinomas. Am J Clin Pathol 116:369-376.
26. Miyata Y, Iwata T, Ohba K, Kanda S, Nishikido M, Kanetake H (2006). Expression of matrix metalloproteinase-7 on cancer cells and tissue endothelial cells in renal cell carcinoma: prognostic implications and clinical significance for invasion and metastasis. Clin Cancer Res 12:6998-7003.
27. Pelosi G, Pastorino U, Pasini F, Maissoneuve P, Fraggetta F, Iannucci A, et al. (2003). Independent prognostic value of fascin immunoreactivity in stage I nonsmall cell lung cancer. Br J Cancer 88:537-547.
28. Piemonte M (2003). TNM - classification of malignant tumors (VI edition - 2002). Innovations in the classification of head and neck neoplasms. Acta Otorhinolaryngol Ital 23:132-135.
29. Puppa G, Maisonneuve P, Sonzogni A, Masullo M, Chiappa A, Valerio M, et al. (2007). Independent prognostic value of fascin immunoreactivity in stage III-IV colonic adenocarcinoma. Br J Cancer 96:1118-1126.
30. Rodrigo JP, Dominguez F, Alvarez C, Manrique C, Herrero A, Suarez C (2002). Expression of E-cadherin in squamous cell carcinomas of the supraglottic larynx with correlations to clinicopathological features. Eur J Cancer 3 8:1059-1064. (Pubitemid 34468010)
31. Rodriguez-Pinilla SM, Sarrio D, Honrado E, Hardisson D, Calero F, Benitez J, Palacios J (2006). Prognostic significance of basal-like phenotype and fascin expression in node-negative invasive breast carcinomas. Clin Cancer Res 1 2:1533-1539.
32. Yoder BJ, Tso E, Skacel M, Pettay J, Tarr S, Budd T, et al. (2005). The expression of fascin, an actin-bundling motility protein, correlates with hormone receptornegative breast cancer and a more aggressive clinical course. Clin Cancer Res 11:186-192.
33. Zhang H, Xu L, Xiao D, Xie J, Zeng H, Cai W, et al. (2006). Fascin is a potential biomarker for early-stage oesophageal squamous cell carcinoma. J Clin Pathol 59:958-964.